Trial Profile
A Phase 1/2, Open Label, Multicenter Study to Investigate the Safety, Pharmacokinetics, and Efficacy of TAS0728, an Oral Covalent Binding Inhibitor of HER2, in Subjects With Advanced Solid Tumors With HER2 or HER3 Abnormalities
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 09 Nov 2022
Price :
$35
*
At a glance
- Drugs TAS-0728 (Primary)
- Indications Advanced breast cancer; Biliary cancer; Colorectal cancer; Endometrial cancer; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Rectal cancer; Solid tumours; Urogenital cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Taiho Oncology
- 09 Dec 2021 Planned End Date changed from 31 Dec 2021 to 30 Jun 2022.
- 09 Dec 2021 Planned primary completion date changed from 31 Dec 2021 to 30 Jun 2022.
- 29 Sep 2021 Planned End Date changed from 31 Aug 2021 to 31 Dec 2021.